ACADIA Pharmaceuticals Inc. Debt/Equity

Debt/Equity of ACAD for past 10 years: annual, quarterly and twelve month trailing (TTM) including Debt/Equity growth rates and interactive chart. The debt-to-equity (D/E) ratio is calculated by dividing a company's total interest-bearing liabilities by its shareholder equity. These numbers are available on the balance sheet of a company's financial statements. The ratio is used to evaluate a company's financial leverage. The debt/equity ratio can be compared to a company's historical average or to peers. A ratio above 1 indicates the company has more debt than equity and a ratio above 3 is considered high. Below 0.5 means the company has little debt and significant capacity to expand it.


Highlights and Quick Summary

  • Debt/Equity for the quarter ending December 30, 2020 was 0.08 (a 5.19% increase compared to previous quarter)
  • Year-over-year quarterly Debt/Equity increased by 460.28%
  • Annual Debt/Equity for 2020 was 0.08 (a 464.29% increase from previous year)
  • Annual Debt/Equity for 2019 was 0.01 (a Infinity% increase from previous year)
  • Annual Debt/Equity for 2018 was 0.0 (a NaN% decrease from previous year)
Visit stockrow.com/ACAD for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Debt/Equity of ACADIA Pharmaceuticals Inc.

Most recent Debt/Equityof ACAD including historical data for past 10 years.

Interactive Chart of Debt/Equity of ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals Inc. Debt/Equity for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 0.08 0.08 0.01 0.01 0.08
2019 0.01 0.01 0.02 0.02 0.01
2018 0.0 0.0 0.0 0.0 0.0
2017 0.0 0.0 0.0 0.0 0.0
2016 0.0 0.0 0.0 0.0 0.0
2015 0.0 0.0 0.0 0.0 0.0
2014 0.0 0.0 0.0 0.0 0.0
2013 0.0 0.0 0.0 0.0 0.0
2012 0.0 0.0 0.0 0.0 0.0
2011 0.0 0.0 0.0 0.0 0.0
2010 0.0 -0.87 0.07 0.0

Business Profile of ACADIA Pharmaceuticals Inc.

Sector: Healthcare
Industry: Biotechnology
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; Trofinetide, a novel synthetic analog for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor for treating cognition and schizophrenia. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.